A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

  • End date
    Jul 14, 2024
  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 14 June 2022
cancer chemotherapy
tumor progression


The purpose of this study is to test any good and bad effects of the study drug 131I-omburtamab. 131I-omburtamab could prevent the cancer from returning, or delay the cancer from getting worse, but it could also cause side effects. Researchers hope to learn more about how 131I-omburtamab works in the body, and how effective it is in treating cancer. 131I-Omburtamab is not approved by the FDA to treat DSRCT or other cancers of the peritoneum.

Condition Desmoplastic Small Round Cell Tumor, Peritoneal Cancer, Peritoneal Carcinoma
Treatment 131 I-omburtamab, WA-IMRT, WAP-IMRT
Clinical Study IdentifierNCT04022213
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on14 June 2022


Yes No Not Sure

Inclusion Criteria

Inclusion Criteria for All Patients
Age >1 year and able to cooperate with radiation safety restrictions during therapy period
Minimum life expectancy of eight weeks as determined by consenting professional
Signed informed consent indicating awareness of the investigational nature of this program
Prior to intraperitoneal catheter placement
At least 1 weeks must have elapsed since prior chemotherapy
At least 2 weeks must have elapsed since prior-radiotherapy or biologic therapy
Toxicities of prior therapy must have resolved to grade 1 or less or to the patient's baseline
At the completion of surgery, patients must fulfill all of the additional following
Group A patients
Have the diagnosis of DSRCT with peritoneal involvement, confirmed at MSK
Have undergone GTR of radiographically evident and visible/palpable disease, as per
surgeon's report
Have no definitive radiological evidence of disease active in liver or outside the
abdomen/pelvic OR have had GTR of this disease at the time of catheter placement
Should not have had prior WAP IMRT
Group B patients
Should not have experienced progression of disease prior to enrollment
Have the diagnosis of DSRCT with peritoneal involvement, confirmed at MSK
Stem cells: Patients must have an autologous hematopoietic stem cell product
Group C patients
cryopreserved and available for re-infusion after 131 I-omburtamab treatment. The
Have radiological evidence of disease (does not need to be in the abdomen) OR
minimum dose for hematopoietic stem cells is 2 x 10^6 CD34+ cells/kg
Have the diagnosis of tumors other than DSRCT, confirmed at MSK
Have a tumor that involves the peritoneum
May or may not have radiological evidence of disease
<20% chance of long term disease-free survival
Omburtamab reactivity must be confirmed by immunohistochemistry except for tumors with
a reported incidence of B7H3 expression of >70%: these include neuroblastoma
melanoma, Ewing's family of tumors, rhabdomyosarcoma, osteosarcoma, Wilm's tumor
hepatoblastoma and rhabdoid tumor (testing for these histologies may be performed if
desired at the discretion of the investigator and after discussion with the prinicipal

Exclusion Criteria

History of allergy to mouse proteins
Active serious infections not controlled by antibiotics
Patients with grade 4 hypersensitivity reaction to radiolabeled iodine
Severe major organ toxicity. Cardiac, pulmonary, and neurologic toxicity should all be
grade 1 or less; Renal, gastrointestinal and hepatic, toxicities should all be grade 2
or less (per NCI CTC version 5)
Platelet count should be >50,000/ul and hemoglobin should be >8gm/dl. Platelet
transfusions are not permitted within one week for blood count demonstrating platelet
count >50,000
Patients with clinically suspected dense intraperitoneal adhesions preventing adequate
IP distribution
Patients previously treated with murine monoclonal antibodies will be excluded if they
have a HAMA level of >1000U/ml (defined as positive)
Pregnant women and women who are breast feeding are excluded for fear of danger to the
fetus/infant. Therefore, negative pregnancy test is required for all women of
child-bearing age, and appropriate contraception is used during the study period and
for 12 months following therapy. Pregnancy testing will be carried out within two
weeks prior to administration of radioiodinated omburtamb in females of childbearing
Inability or unwillingness to comply with radiation safety procedures or protocol
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note